Relationships and Activities. The study is supported by OOO AstraZeneca Phar­maceuticals.

Author:

Shlyakhto E. V.1ORCID,Belenkov Yu. N.2ORCID,Boytsov S. I.3ORCID,Villevalde S. V.1ORCID,Galyavich A. S.4ORCID,Glezer M. G.2ORCID,Zvartau N. E.1ORCID,Kobalava Zh.5ORCID,Lopatin Yu. M.6ORCID,Mareev Yu. V.7ORCID,Tereshchenko S. N.3ORCID,Fomin I. V.8ORCID,Barbarash O. L.9ORCID,Vinogradova N. G.7ORCID,Duplyakov D. V.10ORCID,Zhirov I. V.3ORCID,Kosmacheva E. D.11ORCID,Nevzorova V. A.12ORCID,Reitblat O. M.13ORCID,Soloveva A. E.1ORCID,Zorina E. A.14

Affiliation:

1. Almazov National Medical Research Center

2. I.M. Sechenov First Moscow State Medical University

3. E.I. Chazov National Medical Research Center of Cardiology

4. Kazan State Medical University

5. Peoples’ Friendship University of Russia

6. VolgGMU of the Ministry of Health of Russia, Volgograd

7. Medical Research and Educational Center of the Lomonosov Moscow State University

8. Privolzhsky Research Medical University

9. Research Institute for Complex Issues of Cardiovascular Diseases

10. Samara State Medical University

11. S.V. Ochapovsky Research Institute — Regional Clinical Hospital № 1

12. Vladivostok State Medical University

13. Regional Clinical Hospital № 1

14. OOO AstraZeneca Pharmaceuticals

Abstract

Heart failure (HF) is a global health problem. Despite advances in the development of effective treatments for patients with heart failure, morbidity and mortality from remain high, and the prognosis is poor. However, there is potential to improve outcomes in HF patients with current disease-modifying therapy. Planning needs and resources, assessing the effectiveness of care for HF patients in clinical practice requires high-quality epidemiological data. Previously performed Russian observational studies of HF were characterized by relatively small sample sizes, inclusion of patients in only one or a few regions, strict selection criteria, single-stage design, or short follow-up. The rationale and design of the all-Russian prospective observational multicenter registry study "PRIORITET-CHF", which included 20000 patients with HF throughout the Russian Federation, is presented. The main aims of the study are to (1) describe baseline clinical and demographic characteristics in outpatients with HF in the Russian Federation and (2) characterize routine therapy and evaluate the compliance of treatment for HF with reduced ejection fraction with current clinical guidelines.

Publisher

Silicea - Poligraf, LLC

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3